




Systemic Candidiasis Decision Tree

Jennifer Maple, Pharm.D.
October, 2005

The information contained in this document is intended for informational purposes only and is in no way intended to be a substitute for or in any manner to be construed as medical or clinical advice for any patient in your care. The authors, editors, reviewers, contributors and publishers cannot be held responsible for the accuracy or continued accuracy of the information or for any errors or omissions in the document or for any consequences in the form of liability, loss, injury, or damage incurred as a result of the use and application of any of the information, either directly or indirectly. All medical and clinical decisions regarding any patient's care are the responsibility of the patient's physician.

Copyright ©2005 by Broadlane, Inc., 40 Gold St., San Francisco, CA 94133. All rights reserved. Duplication or distribution of this document without express written permission from Broadlane is prohibited.

Systemic Candidiasis



Renal Impairment = SCr > 2.5 mg/dL or CrCl < 25 mL/min, concomitant nephrotoxic agents, or BMT pts or acute leukemia pts. Patients with end-stage renal disease are not included as renal protection is not needed.
 Echinocandin = caspofungin or micafungin; Lipid Amphotericin B = Abelcet® or Ambisome®
 Normal systemic doses: Fluconazole 400-800 mg po/IV daily, Caspofungin 70 mg IV load, then 50 mg IV daily, **Micafungin 100-150 mg/day IV (TBD)**, Amphotericin B = 0.5-1 mg/kg/day IV, Lipid Amphotericin B = 5 mg/kg/day IV
 Amphotericin B products should be given with an IV saline bolus. Pre-medications may help prevent or lessen infusion-related reactions for amphotericin B products.
 Voriconazole can be considered with intolerance or failure to all agents listed above. Recent FDA approval for non-neutropenic patients; however, studies are limited.